magazine 30 May 2024
Download PDF Page flip version
What to do when your favourite fund manager leaves and what makes the UK's largest listed company, AstraZeneca, tick.
Prime minister Rishi Sunak surprised investors with the 4 July date
The retailer’s turnaround strategy is delivering results and improving consumer confidence offers a tailwind
Sector investors have been getting jittery after soft guidance from Palo Alto
New figures show what parents dole out across the UK
The company is building a presence in the luxury branded jewellery sector
Value of intra-day move 21% more than UK largest company, AstraZeneca
Our resident expert helps with a question on different retirement saving options
AstraZeneca initiated around 30 late-stage clinical trials in 2023
One fund is raising capital with the aim of doing just that
These names span banking, e-commerce, food delivery and internet services
Three things the Franklin Templeton emerging markets team are thinking about right now
Cheap valuations continue to attract bidders but UK plc is no pushover
Keeping the drug development pipeline stocked up is key to delivering consistent growth
There are underlying reasons why medium-sized firms can shine
News of a snap election has derailed hopes of an early rate cut, however
Vet services group’s low valuation more than compensates for the risks of an adverse CMA decision
Analysts are confident of a widespread sector rally, and an ETF is the way to get access
The household appliance innovator is gaining market share around the globe and has positive forecast momentum
Examining what we can learn from the performance of different super sectors
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
